Dr. Jennifer Lund explained the immune response to COVID.
Dr. Julie McElrath provided context about subunit protein vaccines, like those made by Novavax and Sanofi.
Dr. Julie McElrath noted that COVID vaccines continue to prevent hospitalization and death.
Dr. Julie McElrath and collaborators from the Allen Institute discussed research in immune response and understanding long COVID.
Dr. Jim Kublin spoke with CNN about next-gen vaccine delivery technologies.
GeekWire covered Fred Hutch’s Science Says virtual event where Hutch scientists discussed their latest work.
Dr. Andy McGuire discussed findings from the Seattle COVID Cohort Study showing a “massive, massive boost” from the vaccine administered to people who had had COVID.
Dr. Jim Kublin reflected on progress in developing COVID-19 vaccines:
Dr. Julie McElrath explained that her team is working to enroll people who “are over 65 years old, those who may have some kind of underlying medical conditions such as heart disease, high blood pressure, diabetes” into the Fred Hutch vaccine trial.
Dr. Julie McElrath discussed several COVID vaccines being tested in phase 3 trials in the Seattle area.
Dr. Jim Kublin discussed the need for volunteers in the COVID-19 clinical trial registry.
Dr. Julie McElrath discussed the benefits of working with the Allen Institute for COVID-19 research.
Dr. Julie McElrath’s work with the Allen Institute to understand the characteristics of an effective COVID-19 immune response was covered by GeekWire.
Dr. Jim Kublin answered questions about the CoVPN program, the challenges of the program and more.
Dr. Jim Kublin discussed the CoVPN program, trial recruitment and vaccine development.
Dr. Jim Kublin explained the CoVPN network, and the goals of the program.
The CoVPN announcement is covered by KING 5.
Dr. Jim Kublin commented on the timeline and goals of the CoVPN network.
Forbes covered the CoVPN announcement and Fred Hutch’s role in the network of clinical trials.
CNN covered the announcement of the CoVPN network, of which Fred Hutch will serve as the coordination center and Dr. Larry Corey as the lead.
Dr. Julie McElrath discussed the COVID Cohort study to gather information on first responders and those who are likely to be exposed to the virus.
Andy McGuire commented on the vaccine development process in reference to COVID-19 vaccine research.
Dr. Julie McElrath estimated when the COVID-19 outbreak will reach its peak and when we might see a lift on physical distancing measures.
Reader’s Digest covered Dr. Justin Taylor’s recent study in Science Immunology on B cell engineering.
Science covered a B cell engineering study led by Dr. Justin Taylor.
GeekWire covered Fred Hutch Dr. Justin Taylor’s recent work using gene editing to protect against HIV and other viruses.
Segment features interviews with malaria researcher Dr. Jim Kublin and study participants Molly Perry and Joelle Mumley who took part in a study coordinated by Kublin at the Fred Hutch-based Seattle Malaria Clinical Trials Center
Segment features interviews with malaria researcher Dr. Jim Kublin and study participants Molly Perry and Joelle Mumley who took part in a study coordinated by Kublin at the Fred Hutch-based Seattle Malaria Clinical Trials Center
A study co-authored by Dr. Jim Kublin and Center for Infectious Disease Research investigator Dr. Stefan Kappe found a promising approach to developing a malaria vaccine
A study co-authored by Dr. Jim Kublin and researchers at the Center for Infectious Disease Research found a promising new approach to developing a malaria vaccine
A study co-authored by Dr. Jim Kublin and researchers at the Center for Infectious Disease Research found a promising approach to developing a malaria vaccine
Story covers a study co-authored by Dr. Jim Kublin and researchers at the Center for Infectious Disease Research that found genetically engineered malaria parasites could be a promising approach to developing a malaria vaccineh
A study co-authored by Dr. Jim Kublin and researchers at the Center for Infectious Disease Research found a promising approach to developing a malaria vaccine
A study co-authored by Dr. Jim Kublin and Center for Infectious Disease Research investigator Dr. Stefan Kappe found a promising approach to developing a malaria vaccine
A study co-authored by Dr. Jim Kublin and researchers at the Center for Infectious Disease Research found a promising new approach to developing a malaria vaccine
A study co-authored by Dr. Jim Kublin and researchers at the Center for Infectious Disease Research found a promising approach to developing a malaria vaccine
Story covers a study co-authored by Dr. Jim Kublin and researchers at the Center for Infectious Disease Research that found genetically engineered malaria parasites could be a promising approach to developing a malaria vaccineh
A study co-authored by Dr. Jim Kublin and researchers at the Center for Infectious Disease Research found a promising approach to developing a malaria vaccine
Article about the quest to develop a malaria vaccine mentions Dr. Jim Kublin, medical director of the Malaria Clinical Trials Center and an investigator at Fred Hutch
Article about the quest to develop a malaria vaccine mentions Dr. Jim Kublin, medical director of the Malaria Clinical Trials Center and an investigator at Fred Hutch
Second in a two-part series about Fred Hutch's HIV vaccine research in South Africa quotes Dr. Larry Corey and Julie McElrath, among others
Second in a two-part series about Fred Hutch's HIV vaccine research in South Africa quotes Dr. Larry Corey and Julie McElrath, among others
Second in a two-part series about Fred Hutch's HIV vaccine research in South Africa quotes Dr. Larry Corey and Julie McElrath, among others
Quotes Dr. Julie McElrath, director of Fred Hutch's Vaccine and Infectious Disease Division
Quotes Dr. Julie McElrath, director of Fred Hutch's Vaccine and Infectious Disease Division